CONSENSUS STATEMENT

European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders

Luuk R. van den Bersselaar1,2 | Luc Heytens3 | Helga C. A. Silva4 | Jens Reimann5 | Giorgio Tasca6 | Óscar Díaz-Cambronero7 | Nicoline Løkken8 | Anna Hellblom9 | Philip M. Hopkins10 | Henrik Rueffert11 | Börge Bastian11 | Juan Jesus Vilchez12 | Robyn Gillies13 | Stephan Johannsen14 | Francis Veyckemans15 | Tino Muenster16 | Andrea Klein17,18 | Ron Litman19 | Heinz Jungbluth20,21 | Sheila Riazi22 | Nicol C. Voermans2 | Marc M. J. Snoeck1

1Malignant Hyperthermia Investigation Unit, Department of Anaesthesiology, Canisius Wilhelmina Hospital Nijmegen, Nijmegen, The Netherlands
2Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands
3Malignant Hyperthermia Research Unit, Departments of Anaesthesiology and Neurology, University Hospital Antwerp, University of Antwerp and Born Bunge Institute, Antwerp, Belgium
4Malignant Hyperthermia Unit, Department of Surgery, Discipline of Anaesthesia, Pain, and Intensive Care, São Paulo Federal University, São Paulo, Brazil
5Department of Neurology, University of Bonn Medical Centre, Bonn, Germany
6UOC of Neurology, A. Gemelli University Polyclinic Foundation, Scientific Institute for Research and Health Care, Rome, Italy
7Malignant Hyperthermia Unit, Department of Anaesthesiology, Perioperative Medicine Research Group, La Fe University and Polytechnic Hospital, Valencia, Spain
8Copenhagen Neuromuscular Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
9Department of Intensive and Perioperative Care, Skåne University Hospital Lund, Lund, Sweden
10Leeds Institute of Medical Research at St James’s, University of Leeds and Malignant Hyperthermia Investigation Unit, St James’s University Hospital, Leeds, UK
11Schkeuditz Helios Clinic, Malignant Hyperthermia Investigation Unit, Department of Anaesthesiology, Intensive Care, Pain Therapy, University Hospital Leipzig, Leipzig, Germany
12Neuromuscular Centre, La Fe Hospital UIP and ERN EURO-NMD, Neuromuscular Research Group at La Fe IIS and CIBERER, Valencia, Spain
13Malignant Hyperthermia Diagnostic Unit, Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Parkville, Victoria, Australia
14Department of Anaesthesiology, Intensive Care, Emergency, and Pain Medicine, Centre for Malignant Hyperthermia, University Hospital Würzburg, Würzburg, Germany
15Paediatric Anaesthesia Clinic, Jeanne de Flandre Hospital, Lille University Hospital Centre, Lille, France
16Department of Anaesthesiology and Intensive Care Medicine, Hospital of the Order of St John of God, Regensburg, Germany
17Department of Paediatric Neurology, University Children’s Hospital UKBB, Basel, Switzerland
18Division of Neuropaediatrics, Development, and Rehabilitation, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
19Department of Anaesthesiology and Critical Care, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
20Department of Paediatric Neurology, Neuromuscular Service, Evelina’s Children Hospital, Guy’s and St Thomas’ Hospital National Health Service Foundation Trust, London, UK
21Randall Centre for Cell and Molecular Biophysics, Muscle Signalling Section, Faculty of Life Sciences and Medicine, King’s College London, London, UK
22Malignant Hyperthermia Investigation Unit, Department of Anaesthesiology and Pain Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada

Luuk R. van den Bersselaar and Luc Heytens are co-first authors.
Nicol C. Voermans and Marc M. J. Snoeck are co-last authors.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
INTRODUCTION

Patients with neuromuscular disorders (NMDs) are at increased risk of peri-operative complications related to anaesthesia. The reasons for this include associated cardiorespiratory morbidity, altered pharmacodynamics of anaesthetics and neuromuscular blocking agents (NMBAs), impaired temperature and glucose regulation, and specific risks associated with certain underlying genetic defects, or a combination of the above [1–3].

Whereas in recent years comprehensive standards of care have been formulated for the more common NMDs such as Duchenne muscular dystrophy (DMD) [4] and spinal muscular atrophy (SMA) [5], there is lack of consensus guidance focusing on the anaesthetic management of NMDs throughout the range of neuromuscular conditions. Neurologists are often asked to share the specific considerations regarding their neuromuscular patients requiring surgery, anaesthesia, or procedural sedation. Furthermore, neurologists who provide follow-up for patients with NMDs are well placed to alert them to any perioperative risks specifically associated with their NMD and the particular precautions to be taken in close liaison with anaesthesiologists [1].

We therefore present the European Neuromuscular Centre (ENMC) consensus statement on anaesthesia in patients with neuromuscular disorders as formulated during the 259th ENMC Workshop on Anaesthesia in Neuromuscular Disorders [6]. This consensus statement provides a comprehensive and accessible overview with the aim of guiding neurologists and anaesthesiologists, improving perioperative safety, and optimizing risk assessment and appropriate management of these patients.

METHODS

Our approach to developing this consensus statement was performed according to the AGREE II (Appraisal of Guidelines for Research & Evaluation) reporting checklist [7].
ENMC workshop

For the 259th ENMC Workshop on Anaesthesia in Neuromuscular Disorders, 30 international experts in the field of (paediatric) anaesthesia, neurology, and genetics were selected by the workshop organizers (N.C.V., M.M.J.S., S.R., H.J.) based on their particular expertise in anaesthesia and/or NMDs and geographic balance. The ENMC research board approved the participants list. The virtual workshop consisted of three parts:

(i) Anaesthetic management of various NMDs (11 December 2020);
(ii) New developments in the field of malignant hyperthermia (MH) and increasing awareness (28 May 2021); and

The comprehensive workshop report has been published separately [6] but did not allow for the inclusion of the full anaesthesia considerations included in this paper.

In preparation for the ENMC workshop, the organizers conducted a literature search covering the period 1 January 2000 to 14 July 2021 in PubMed and Embase using the methodological framework for scoping reviews [8]. The main findings of this literature search were disseminated to the participants and presented during the first part of the workshop. Furthermore, six couples of workshop participants were invited to present the existing evidence and their expert opinion for anaesthetic management in specific groups of NMDs (see below). These participants provided a written summary of their recommendations, which were merged into a preliminary version of this consensus statement. The presenters were subsequently invited to participate in a virtual meeting to discuss the preliminary consensus statement. After the initial evaluation, a revised version was distributed as a basis for discussion during the second part of the ENMC workshop. Subsequently, the preliminary consensus statement document was modified according to the discussion at the second workshop session and distributed by email. Consensus regarding the consensus statement content was reached after further communication by email. Finally, the consensus statement content was subjected to a modified Delphi process [9]. The whole process description is summarized in Figure 1.

![Figure 1](image-url)
Modified Delphi process

The consensus statement drafted following the ENMC workshop and subsequent meetings was distributed among its coauthors (n = 22). They were asked to indicate their agreement with each recommendation on a 9-point scale (score 1: absolutely disagree, score 9: absolutely agree). Given the variable and specific expertise of the workshop participants, for some of them the full content of this consensus statement was not completely within their area of expertise. The participants were asked to abstain from voting if a specific recommendation was not within their area of expertise. The level of agreement for each recommendation is presented as the median score and the percentage of participants who scored ≥7. Consensus was defined as a median score of ≥7 and at least 70% of the respondents scoring the recommendation ≥7.

Focus and approach

This consensus statement entails general recommendations applicable to all patients with NMDs who need anaesthesia or procedural sedation and group-specific recommendations for:

- Neuromuscular junction disorders;
- Muscle channelopathies (nondystrophic myotonia and periodic paralysis);
- Myotonic dystrophy (types 1 and 2);
- Muscular dystrophies;
- Congenital myopathies and dystrophies; and
- Mitochondrial and metabolic myopathies.

Suggested relevant topics were risks, myopathy-related treatment, preoperative diagnosis and management, specific recommendation for anaesthesia including nonanaesthetic drugs used in the perioperative phase, and specific recommendations for postoperative care.

We restricted detailed clinical information concerning the six main groups of NMDs to what was essential for our purpose. For complementary disease-specific anaesthesia considerations, we refer to the following databases:

- OrphanAnesthesia (https://www.orphananesthesia.eu/en/); and

As we consider the American Society of Anesthesiologists physical status classification [10] too unspecific for this particular patient population, we devised a practical risk assessment tool with a scoring matrix based on the NARCO-SS-Risk Assessment Tool [11] and the matrix model developed by Schieren et al. [2].

Level of evidence

The level of evidence for each recommendation has been adapted from the Scottish Intercollegiate Guidelines Network grading system [12] and is indicated in each paragraph:

- Level 1+: high-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with very low risk of bias;
- Level 1−: meta-analyses, systematic reviews or RCTs with high risk of bias;
- Level 2+: systematic reviews or case–control or cohort studies with low risk of bias;
- Level 2−: case–control or cohort studies with high risk of bias, animal studies;
- Level 3: case reports, case series; and
- Level 4: expert opinion.

RESULTS

Modified Delphi process

A total of 20 participants (90.9%) responded. During the modified Delphi process, consensus was reached for all recommendations.

LEVEL 1: GENERAL RECOMMENDATIONS FOR PATIENTS WITH NMDs

Surgery setting

Surgery and the associated need for sedation and/or anaesthesia pose a burden on the neuromuscular patient. They should only receive anaesthesia or sedation in the setting of a 24-h high-care facility [1–3].

Level of evidence: 4

The median score by the modified Delphi process was 9. Respondents who scored ≥7 totaled 18 of 19 (94.7%); one respondent abstained from voting.

Anaesthesia technique

Surgery or diagnostic procedures should be performed using regional anaesthesia if possible, preferably as a single technique or alternatively in combination with general anaesthesia [1–3].
Preoperative assessment

A clear understanding of the confirmed or suspected neuromuscular diagnosis, degree of muscle weakness, and current treatment and awareness of associated cardiorespiratory manifestations are paramount for the preoperative assessment. Cardiomyopathy or cardiac conduction defects can be part of certain NMDs [13–17]. Due to respiratory muscle weakness and spinal deformities, there is an increased risk of restrictive lung disease [16, 18–20]. Furthermore, chronic hypoxaemia and pulmonary hypertension may lead to cor pulmonale, which must be considered during the preoperative examination [13]. This information can be partly obtained from the history or physical examination, but ancillary assessments may be necessary.

A careful preoperative examination, multisystem evaluation, and clear communication among anaesthesiologists, surgeons, cardiologists, pneumologists, and neurologists are crucial. During the preoperative assessment, specific attention should be paid to craniofacial abnormalities indicating a difficult airway [21]. Depending on the procedure, additional preoperative investigations may include electrocardiography (ECG), chest X-ray, echocardiography, Holter examination, lung function tests (in the sitting and supine positions), polysomnography, and blood tests including arterial blood gases, haemoglobin, electrolytes, lactate, creatine kinase (CK), and liver and kidney function tests [1–3, 13–20, 22].

Some neuromuscular patients are treated with anticholinesterase inhibitors, antiarrhythmic drugs, antisense oligonucleotides, steroids, or other immunosuppressive agents [4, 23]. This needs to be recorded and evaluated during the preoperative assessment.

Premedication

Patients with NMDs have an increased sensitivity to sedatives and anaesthetics [1–3]. Premedication with benzodiazepines may result in central respiratory depression, airway obstruction, and/or worsening of muscle weakness. Premedication should therefore be avoided, and if absolutely required only be used in reduced doses with concurrent pulse oximetry (SpO₂) and respiratory rate monitoring [1–3].

Preoperative fasting

Patients with NMDs should be scheduled for surgery as the first case of the day, because prolonged fasting may cause hypoglycaemia, in particular in patients with reduced muscle mass [24–26].

Body temperature management

Anaesthesia causes drop in body temperature due to vasodilation and blunting of thermoregulatory reflexes. This effect is more pronounced in neuromuscular patients because of their reduced muscle mass. Moreover, hypothermia further increases sensitivity to sedatives, anaesthetic agents, and nondepolarizing NMBAs [29]. Preoperative warming reduces the fall in core temperature following induction of anaesthesia in the general population [30] and will be even more beneficial in patients with NMDs.
Level of evidence: 4

The median score by the modified Delphi process was 9. Respondents who scored ≥7 totaled 19 of 19 (100%); one respondent abstained from voting.

On the other hand, increased muscle activity (cramps, myotonia) or excessive external heating can result in hyperthermia with increased muscle tone, cramps, and rhabdomyolysis. Therefore, continuous temperature monitoring is recommended.

Level of evidence: 4

The median score by the modified Delphi process was 9. Respondents who scored ≥7 totaled 18 of 18 (100%); two respondents abstained from voting.

General anaesthesia

Short-acting opioids, sedatives, and hypnotic agents are preferred to minimize respiratory depression on emergence from anaesthesia [1–3].

Level of evidence: 4

The median score by the modified Delphi process was 9. Respondents who scored ≥7 totaled 18 of 18 (100%); two respondents abstained from voting.

Neuromuscular blocking agents

Based on their mechanisms of action, NMBAs can be divided into depolarizing NMBAs and nondepolarizing NMBAs [1]. Patients with an NMD are at greatest risk for succinylcholine-induced hyperkalemia [31–34]. Hence, succinylcholine should not be used in patients with a known or suspected NMD.

Level of evidence: 2–

The median score by the modified Delphi process was 9. Respondents who scored ≥7 totaled 14 of 16 (75%); four respondents abstained from voting.

Most neuromuscular patients have an increased sensitivity to nondepolarizing NMBAs because of the reduced muscle mass and strength. A lower initial dose may be sufficient to achieve adequate muscle relaxation. Duration of action is often prolonged, and effects of residual relaxation are more severe than in normal patients [35–38]. The effect of NMBAs should be measured by quantitative neuromuscular monitoring to prevent residual neuromuscular blockade following emergence from anaesthesia and extubation.

Level of evidence: 2+

The median score by the modified Delphi process was 9. Respondents who scored ≥7 totaled 18 of 18 (100%); two respondents abstained from voting.

When a nondepolarizing NMBA is used, extubation and emergence from anaesthesia should be guided by a train-of-four ratio of 1.0. Any residual and potentially clinically relevant muscle relaxation at the end of the intervention should preferably be reversed with sugammadex as a specific pharmacological antagonist of rocuronium and vecuronium [39–41]. Due to the effectiveness of sugammadex, the latter two nondepolarizing NMBAs should be given preference. When there is residual neuromuscular blockade after use of other NMBAs or sugammadex is unavailable, extubation and emergence from anaesthesia should be postponed until baseline muscular strength has recovered spontaneously. In this scenario, postoperative sedation and ventilatory support are necessary.

Level of evidence: 2–

The median score by the modified Delphi process was 8. Respondents who scored ≥7 totaled 12 of 16 (75%); four respondents abstained from voting.

Reversal of muscle relaxation using cholinesterase inhibitors is contraindicated because of side effects in myotonic dystrophies [42, 43] and some congenital myasthenic syndromes. Cholinesterase inhibitors (e.g., neostigmine) are undesirable in other neuromuscular patients because of the unpredictable pharmacodynamics and the increased sensitivity to NMBAs.

Level of evidence: 2–

The median score by the modified Delphi process was 8. Respondents who scored ≥7 totaled 12 of 16 (75%); four respondents abstained from voting.

Volatile anaesthetics

Volatile anaesthetics are only strictly contraindicated in patients with NMDs with variants in the RYR1 gene because of the possibility of MH susceptibility [44–50], unless the specific variant has been classified as benign for MH according to the ClinGen Variant Curation Expert Panel recommendations for RYR1 pathogenicity classifications in MH susceptibility [51]. Patients with variants in the
**Level of evidence: 2+**

The median score by the modified Delphi process was 8. Respondents who scored ≥7 totaled 11 of 15 (73.3%); five respondents abstained from voting.

NMDs without these specific genetic backgrounds might be associated with other, rare adverse effects, such as anaesthesia-induced rhabdomyolysis (AIR) in DMD or Becker muscular dystrophy (BMD) patients [33, 34]. The prolonged effect of NMBAs when used in combination with volatile anaesthetics also has to be taken into account [52].

**Level of evidence: 2+**

The median score by the modified Delphi process was 9. Respondents who scored ≥7 totaled 18 of 18 (100%); two respondents abstained from voting.

Hence, anaesthesiologists are advised against the prolonged use of volatile anaesthetics in patients with NMDs. Although often recommended as an alternative, total intravenous anaesthesia (TIVA; most frequently based on a propofol, short-acting benzodiazepines, or dexmedetomidine-based technique in combination with short-acting potent opioids) has other risks [53–56]. This is an important consideration as part of a comprehensive risk–benefit assessment between TIVA and volatile anaesthetic-based techniques.

Specific indications for use of volatile anaesthetics (which can be administered through a face mask) in patients with an NMD might include situations where awake intravenous access is not tolerated or may be difficult or impossible (e.g., in anxious children).

**Level of evidence: 4**

The median score by the modified Delphi process was 8. Respondents who scored ≥7 totaled 16 of 18 (88.9%); two respondents abstained from voting.

Early mobilization and feeding after surgery should be pursued. Respiratory physiotherapy can improve breathing and facilitate coughing.

**Medical alert cards, apps, and warnings in electronic patient files**

Many patient advocacy organizations provide medical alert cards to patients with NMDs. These cards improve patient safety, supporting individuals and their families in relaying information to emergency services and other medical professionals. Specific and personalized disease information, possible complications, and their specific treatments should be recorded in such formats.

Neurologists and rehabilitation specialists who provide follow-up for patients with NMDs are in an excellent position to alert their patients regarding perioperative risks and the specific precautions to be taken. Through annual review at follow-up visits, medical professionals can contribute to the improved use of medical alert cards. Medical alerts should be clearly visible in electronic health records, and recommendations for essential perioperative precautions should be included in correspondence with other health care providers.

**Level of evidence: 4**

The median score by the modified Delphi process was 9. Respondents who scored ≥7 totaled 19 of 19 (100%); one respondent abstained from voting.

**LEVEL 2: GROUP-SPECIFIC RECOMMENDATIONS**

In addition to the general recommendations summarized above, this section gives disease-specific recommendations concerning the six groups of NMDs.
Neuromuscular junction disorders

Disorders of the neuromuscular junction may be caused by pathogenic antibodies, genetic defects [57], specific drugs, and/or toxins that interfere with the normal signalling between the presynaptic nerve ending and the postsynaptic muscle membrane [58].

Acquired autoimmune disorders of the neuromuscular junction are the most common and include myasthenia gravis [58, 59] and Lambert-Eaton myasthenic syndrome (LEMS). LEMS is frequently associated with an underlying malignancy or another autoimmune process.

Congenital myasthenic syndromes are a phenotypically heterogeneous group of disorders due to a variety of genetic defects resulting in impaired neuromuscular transmission. Muscle weakness typically begins in early childhood, but presentation may be delayed until adolescence or adulthood. Facial muscles, including (extra) ocular and bulbar muscles, are the most consistently affected. Due to muscle weakness, affected infants may have feeding difficulties. Motor development may be delayed. The severity of the myasthenia varies greatly, ranging from an inability to walk to only minor weakness. Weakness may be exacerbated by fever or infection [57, 58]. Specific anaesthesia considerations for patients with neuromuscular junction disorders are summarized in Table 1.

Muscle channelopathies

Skeletal muscle channelopathies are rare clinically and genetically heterogeneous diseases. They are characterized by altered muscle fibre excitability caused by mutations affecting voltage-gated ion channels such as chloride channel (CLC-1), sodium channel (NaV1.4), calcium channel (CaV1.1), or potassium channels (KIR2.1, KIR2.6, KIR3.4). The clinical manifestations vary from an inability to relax after voluntary contraction (myotonia) to transient attacks of generalized or focal flaccid muscle weakness (periodic paralysis). Fluctuation of symptoms are strongly affected by environmental triggers such as exercise, temperature changes, pain, emotional factors, fasting, or alterations in serum potassium concentration [63]. The nondystrophic myotonias include myotonia congenita (due to variants in CLCN1), paramyotonia congenita (due to variants in SCN4A), and sodium channel myotonia (SCN4A) [23]. Periodic paralyses include hyperkalaemic periodic paralysis caused by variants in SCN4A and hypokalaemic periodic paralysis (hypoPP) caused by variants in CACNA1S, SCN4A [23, 64], or rarely RYR1 [65], and Andersen–Tawil syndrome caused by variants in KCNJ2 [66]. Andersen–Tawil syndrome is associated with ECG abnormalities (long Q-T interval and U-waves) and predisposition to life-threatening ventricular arrhythmias [14].

Up to 31% of patients with muscle channelopathies report worsening of symptoms and a prolonged recovery time after general anaesthesia [67]. There are reports of myotonic crises in patients with myotonias and prolonged paralysis (hyperkalaemic triggered by succinylcholine or other potassium-releasing agents in patients with SCN4A variants and hypokalaemic related to hypokalaemia and hyperglycaemia following anaesthesia) [67, 68].

Variants in CACNA1S and, very rarely, RYR1 are associated with hypoPP, and although none of these RYR1 variants has been shown to predispose to MH, the risk is difficult to disprove [65, 67, 69]. A patient with known hypoPP who had a confirmed episode of MH [69] has subsequently been found to harbour a CACNA1S variant pathogenic for hypoPP but also a second variant in CACNA1S and two variants in RYR1 [48] (unpublished data, P.M.H.). Specific anaesthesia considerations for patients with muscle channelopathies are summarized in Table 2.

Myotonic dystrophy types 1 and 2

Myotonic dystrophy type 1 (DM1) is a frequent adult muscular dystrophy caused by DNA triplet repeat expansion in the DMPK gene. Larger expansions lead to the infantile or more severe, congenital form resembling a congenital muscular dystrophy, with often profound associated weakness, hypotonia, and bulbar and respiratory involvement. A second form, myotonic dystrophy type 2 (DM2), results from a different repeat expansion in the CNBP gene, showing more proximal weakness [71].

Both disorders have autosomal dominant inheritance and multisystem features, including a myotonic myopathy, cataract, cardiac conduction defects, central and obstructive sleep apnoea, and a range of endocrine abnormalities including diabetes mellitus [71]. Respiratory impairment is more common and more pronounced in DM1.

Much of the available literature does not differentiate the congenital form of DM1 from its other forms, although CTG repeat analysis [72] and grading by presence of proximal weakness [72, 73] argue for a higher risk of complications in the congenital form. Furthermore, myotonia is usually absent in the early life of patients with this form. Specific anaesthesia considerations for patients with DM1 and DM2 are summarized in Table 3.

Muscular dystrophies

Several different skeletal muscle disorders, with very different degrees of severity and characterized by various pathophysiological mechanisms, are classified under the definition of muscular dystrophies. These disorders vary widely with regard to age at onset, degree of motor impairment, and associated cardiorespiratory involvement [80]. Classification is based on the underlying gene defect. This paragraph will focus on the most common forms, the dystrophinopathies, limb girdle muscular dystrophies (LGMDs), facioscapulohumeral muscular dystrophy (FSHD), and oculopharyngeal muscular dystrophy (OPMD).

Dystrophinopathy refers to DMD and BMD due to hemizygous X-linked variants in the DMD gene, encoding dystrophin. Ventilatory support and steroid treatments have improved survival in boys with DMD significantly and have prolonged ambulation, reduced the risk of developing scoliosis, and improved cardiac health [80]. Severe
Table 1: Specific anaesthesia recommendations for neuromuscular junction disorders

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>SIGN</th>
<th>Median score, modified Delphi process</th>
<th>Respondents who scored ≥7, n</th>
<th>Abstained from voting, n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Specific considerations for myasthenia gravis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Elective surgery should preferably be performed when the condition is stable with the patient requiring low doses of immunomodulatory medication and preferably as first case of the day when the weakness is least pronounced [59].</td>
<td>4</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• Consider postoperative complications:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Myasthenic crisis: severe respiratory muscle weakness that requires intubation or causes delayed extubation after surgery, linked to cholinergic deficit. Urgent therapy is needed with intravenous pyridostigmine, plasma exchange, immunoglobulins, and/or supportive care [59].</td>
<td>4</td>
<td>9</td>
<td>18/19 (94.7%)</td>
<td>1</td>
</tr>
<tr>
<td>• Cholinergic crisis: identified by the mnemonic &quot;SLUDGE&quot;: Salivation, Lacrimation, Urination, Defecation, Gastrointestinal distress, and Emesis. Antimuscarinic (atropine) drugs must be given [59].</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• An intravenous hydrocortisone stress regimen should be considered in patients who are or were recently (&lt;1 year) on a course of corticosteroids (prednisolone ≥5 mg/day for &gt;1 month) [60].</td>
<td>4</td>
<td>8</td>
<td>15/17 (88.2%)</td>
<td>3</td>
</tr>
<tr>
<td>• Anticholinesterase agents should be continued until prior to surgery but stopped during anaesthesia.</td>
<td>4</td>
<td>9</td>
<td>17/19 (89.5%)</td>
<td>1</td>
</tr>
<tr>
<td>• Any immunosuppressive therapy other than steroids can be withheld on the day of surgery.</td>
<td>4</td>
<td>8</td>
<td>16/17 (94.1%)</td>
<td>3</td>
</tr>
<tr>
<td>• Inform the patient about the increased risk for perioperative complications, mainly postoperative pulmonary complications, myasthenic crisis, and postoperative residual neuromuscular blockade [59].</td>
<td>4</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td><strong>Intraoperative recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• TIVA and volatile anaesthetics have both been used effectively and safely and should be adapted to the case and surgery in question [59, 61, 62].</td>
<td>2−</td>
<td>9</td>
<td>15/15 (100%)</td>
<td>5</td>
</tr>
<tr>
<td>• Use of sugammadex rather than neostigmine is associated with a lesser risk of myasthenic crisis after thymectomy in adult myasthenia gravis patients [41].</td>
<td>2−</td>
<td>8.5</td>
<td>14/14 (100%)</td>
<td>6</td>
</tr>
<tr>
<td><strong>Postoperative recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Restart oral medication as soon as possible [59].</td>
<td>4</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• If intravenous administration of anticholinesterase agents is required, the dose should be adjusted:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Dose of oral pyridostigmine: intravenous pyridostigmine = 30:1 [59];</td>
<td>4</td>
<td>9</td>
<td>16/16 (100%)</td>
<td>4</td>
</tr>
<tr>
<td>• Dose of oral pyridostigmine: intravenous neostigmine = 60:0.5 [58].</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>However, caution is needed, as there are large interindividual differences in bioavailability.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Pyridostigmine can also be administered by continuous infusion when the dose is adjusted accordingly. Following dose conversion as outlined above, the infusion can be terminated, and oral anticholinergics restarted at any point.</td>
<td>4</td>
<td>9</td>
<td>13/13 (100%)</td>
<td>7</td>
</tr>
</tbody>
</table>

Note: For each recommendation, the level of evidence according to the SIGN criteria and the level of agreement are given by the median voting results and the percentage of respondents with a voting result ≥7.

Abbreviations: SIGN, Scottish Intercollegiate Guidelines Network; TIVA, total intravenous anaesthesia.

Cardiorespiratory involvement is common and needs thorough evaluation during the preoperative assessment [13, 17]. Macroglossia and contracture of neck muscles can cause problems for intubation. Central nervous system (CNS) involvement manifesting as cognitive deficits, speech problems, and psychiatric comorbidities such as anxiety and depression may complicate preoperative counselling [81].
LGMDs are a genetically heterogeneous group of disorders characterized by predominantly proximal muscle weakness and onset after becoming able to walk [80]. Specific forms (e.g., sarcoglycanopathies and alpha-dystroglycanopathies) may be associated with cardiac involvement, usually dilated cardiomyopathy or, rarely, arrhythmogenic heart disease, which is frequent in POPDC1-related LGMD R25 [15, 16]. Respiratory failure may be a feature of the most severe forms or of those with spinal deformities, such as the COL6-related LGMDs. Significant tongue enlargement, which can cause problems for intubation, is occasionally present in FKRP-related LGMD R9, DMD, and sarcoglycanopathies [16, 21].

OPMD is another late onset mostly autosomal dominant disorder caused by a trinucleotide repeat expansion in the first exon of the polyadenylate-binding protein nuclear 1 gene (PABPN1). The main clinical issues are ptosis and dysphagia, although patients may later also develop proximal muscle weakness. Specific anaesthesia considerations for patients with muscular dystrophies are summarized in Table 4.

**Congenital myopathies and congenital muscular dystrophies**

Congenital myopathies and congenital muscular dystrophies are disorders with early onset muscle weakness. Both groups give rise to proximal, axial, and often facial weakness with slow progression and cardiorespiratory impairment, as well as joint contractures.

### TABLE 2 Specific anaesthesia recommendations for muscle channelopathies

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>SIGN</th>
<th>Median score, modified Delphi process</th>
<th>Respondents who scored ≥7, n</th>
<th>Abstained from voting, n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preoperative recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Perform ECG and 24-h Holter monitoring in patients with Andersen–Tawil syndrome and other patients treated with antiarrhythmic drugs [14].</td>
<td>2+</td>
<td>9</td>
<td>18/18 (100%)</td>
<td>2</td>
</tr>
<tr>
<td>• Inform the patient that the procedure might exacerbate and/or precipitate an attack, resulting in prolonged postsurgical recovery [67].</td>
<td>2+</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• In patients with RYR1 and/or CACNA1S variants, referral to an MH investigation centre, if possible, is recommended for advice on the risk of MH and use of volatile anaesthetics [44]. In case it is not possible to contact an MH investigation centre before surgery, e.g., in the case of emergency surgery, use of volatile anaesthetics and/or succinylcholine is contraindicated in patients with RYR1 and/or CACNA1S variants [70].</td>
<td>2+</td>
<td>9</td>
<td>18/19 (94.7%)</td>
<td>1</td>
</tr>
<tr>
<td>• Succinylcholine should be avoided irrespective of the risk of MH [23, 68].</td>
<td>2+</td>
<td>9</td>
<td>18/18 (100%)</td>
<td>2</td>
</tr>
<tr>
<td><strong>Intraoperative recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Potassium supplementation in patients with paramyotonia congenita can trigger myotonia and should be avoided. In case of fasting, regular control of potassium serum levels is recommended.</td>
<td>3</td>
<td>9</td>
<td>17/17 (100%)</td>
<td>3</td>
</tr>
<tr>
<td>• Avoid hypothermia, shivering, and agitation, as these can cause myotonia [68].</td>
<td>3</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• Avoid high glucose levels and hyperventilation (potentially causing alkalosis) in hypoPP [68].</td>
<td>3</td>
<td>9</td>
<td>16/16 (100%)</td>
<td>4</td>
</tr>
<tr>
<td>• Avoid hyperkalaemia and hypoventilation (potentially causing acidosis) in hyperPP.</td>
<td>3</td>
<td>9</td>
<td>16/16 (100%)</td>
<td>4</td>
</tr>
<tr>
<td>• Patients treated with mexiletine should not receive class I antiarrhythmics due to the risk of conduction block.</td>
<td>3</td>
<td>9</td>
<td>13/13 (100%)</td>
<td>7</td>
</tr>
<tr>
<td>• Succinylcholine and/or acetylcholinesterase inhibitors should be avoided, as these may induce myotonia [68].</td>
<td>3</td>
<td>9</td>
<td>18/18 (100%)</td>
<td>2</td>
</tr>
</tbody>
</table>

Note: For each recommendation, the level of evidence according to the SIGN criteria and the level of agreement are given by the median voting results and the percentage of respondents with a voting result ≥7.

Abbreviations: ECG, electrocardiography; hyperPP, hyperkalaemic periodic paralysis; hypoPP, hypokalaemic periodic paralysis; MH, malignant hyperthermia; SIGN, Scottish Intercollegiate Guidelines Network.
and scoliosis. Despite some overlap, anaesthetic implications are different.

**Congenital muscular dystrophies**

Congenital muscular dystrophies are classically defined as a group of disorders characterized by onset in the first 6 months of life and muscle biopsy evidence of a muscular dystrophy with histopathological features of de- and regeneration [85]. Depending on the underlying disease, cardiorespiratory involvement can be prominent, and some forms may have associated CNS involvement with epilepsy. The genes associated can be classified according to the cellular localization of the encoded protein into the following groups: proteins of the plasma membrane–extracellular matrix interface such as collagen 6 (COL6A1, 2, 3), merosin, or laminin α2 (LAMA2), integrin α7 (ITGA7), proteins

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>SIGN</th>
<th>Median score, modified Delphi process</th>
<th>Respondents who scored ≥7, n</th>
<th>Abstained from voting, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preoperative recommendations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Preoperative screening should include ECG, echocardiography, and lung function tests (in sitting and the supine position), with review of current medication and therapies (e.g., pacemakers, noninvasive ventilation). A neurological examination should be performed to document the degree of muscle weakness, as proximal weakness indicates a greater risk of complications in DM1 [72, 73].</td>
<td>2−</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• CNS involvement manifesting as lack of initiative and compliance may complicate preoperative counselling [74].</td>
<td>2−</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• Consider antacid treatment as aspiration prophylaxis due to gastrointestinal dysmotility [42, 43].</td>
<td>4</td>
<td>7</td>
<td>13/17 (76.5%)</td>
<td>3</td>
</tr>
<tr>
<td><strong>Intraoperative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Regional anaesthesia, TIVA, and volatile anaesthetics have been used effectively and safely, although rigidity cannot always be prevented [42, 43, 75, 76].</td>
<td>3</td>
<td>9</td>
<td>15/15 (100%)</td>
<td>5</td>
</tr>
<tr>
<td>• Use of opioids should be avoided if possible, as there is increased sensitivity to such drugs, with an increased risk of respiratory [77] (and possibly intestinal) complications [72]; if this is not possible, use short-acting opioids.</td>
<td>3</td>
<td>8</td>
<td>14/17 (82.4%)</td>
<td>3</td>
</tr>
<tr>
<td>• Pain, cold, electrical or mechanical stimulation, and drugs that increase muscle membrane excitability may occasionally trigger myotonia [76], which may be resistant to pharmacological treatment.</td>
<td>3</td>
<td>8.5</td>
<td>18/18 (100%)</td>
<td>2</td>
</tr>
<tr>
<td><strong>Postoperative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Avoid the use of opioids if possible [72, 77].</td>
<td>4</td>
<td>9</td>
<td>17/19 (89.5%)</td>
<td>1</td>
</tr>
<tr>
<td>• Monitoring should include CO₂ measurements, as the hypercapnic response is diminished, also considering that excessive sleepiness may be part of the disease spectrum [74].</td>
<td>4</td>
<td>9</td>
<td>16/19 (84.2%)</td>
<td>1</td>
</tr>
<tr>
<td>• Early home discharge is not recommended, as there is an increased risk of having prolonged ileus due to intestinal dysmotility.</td>
<td>4</td>
<td>9</td>
<td>16/18 (88.9%)</td>
<td>2</td>
</tr>
<tr>
<td><strong>Specific considerations for Myotonic Dystrophy type II (DM2)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• The same recommendations as for DM1 as outlined above apply; however, the overall complication rate appears to be lower [78, 79].</td>
<td>2−</td>
<td>9</td>
<td>15/15 (100%)</td>
<td>5</td>
</tr>
<tr>
<td>• In a few cases, a postoperative CK rise and increased muscle complaints have been reported [78].</td>
<td>2−</td>
<td>9</td>
<td>14/14 (100%)</td>
<td>6</td>
</tr>
</tbody>
</table>

Note: For each recommendation, the level of evidence according to the SIGN criteria and the level of agreement are given by the median voting results and the percentage of respondents with a voting result ≥7.

Abbreviations: CK, creatine kinase; CNS, central nervous system; DM1, myotonic dystrophy type 1; DM2, myotonic dystrophy type 2; ECG, electrocardiography; SIGN, Scottish Intercollegiate Guidelines Network; TIVA, total intravenous anaesthesia.
in O-glycosylation of the dystrophin-associated glycoprotein (POMT1, POMT2, POMGnT1, LARGE, FKTN, FKRP, ISPD) and other intracellular proteins such as lamin A/C (LMNA), an intermediate filament located at the inner nuclear membrane, and selenoprotein N (SELENON), a protein with redox and calcium level regulation function [80].

It should be noted that the clinical phenotype of congenital DM1 (see paragraph above) is more similar to this group of diseases than to the adult forms of myotonic dystrophy. Specific anaesthesia considerations for patients with congenital muscular dystrophies are summarized in Table 5a.
TABLE 5 Specific anaesthesia recommendations for congenital muscular dystrophies (a) and congenital myopathies (b)

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>SIGN</th>
<th>Median score, modified Delphi process</th>
<th>Respondents who scored ≥7, n</th>
<th>Abstained from voting, n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(a) Specific anaesthesia recommendations for congenital muscular dystrophies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative recommendations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Evaluate the need for fibre-optic tracheal intubation in the presence of craniofacial abnormalities. In some forms with spinal rigidity and markedly reduced neck movement (in particular those due to variants in LMNA, COL6A, LAMA2, or SELENON) [80], intubation may be difficult.</td>
<td>3</td>
<td>9</td>
<td>17/17 (100%)</td>
<td>3</td>
</tr>
<tr>
<td>• Specific attention to potential cardiac involvement should be paid in forms due to variants in LAMA2, LMNA and the alpha-dystroglycanopathies.</td>
<td>3</td>
<td>9</td>
<td>16/16 (100%)</td>
<td>4</td>
</tr>
<tr>
<td>• Respiratory involvement should be considered in patients with variants in SELENON, COL6, and LAMA2, and the alpha-dystroglycanopathies [80].</td>
<td>3</td>
<td>9</td>
<td>15/15 (100%)</td>
<td>5</td>
</tr>
<tr>
<td>Intraoperative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• More specific considerations depend on the underlying pathology.</td>
<td>4</td>
<td>9</td>
<td>17/17 (100%)</td>
<td>3</td>
</tr>
<tr>
<td>• There is no association with MH.</td>
<td>4</td>
<td>9</td>
<td>18/18 (100%)</td>
<td>2</td>
</tr>
<tr>
<td>• We have not found any reports of AIR associated with dystrophies other than DMD and BMD but cannot exclude the hypothetical risk of AIR on exposure to volatile anaesthetics. TIVA and volatile anaesthetics have both been used effectively and safely and should be adapted to the case and surgery in question.</td>
<td>4</td>
<td>8</td>
<td>17/17 (100%)</td>
<td>3</td>
</tr>
<tr>
<td>Postoperative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Nutrition needs to be monitored, as reduced muscle mass can cause postoperative hypoglycaemia up to several days after surgery [24, 26].</td>
<td>3</td>
<td>9</td>
<td>15/15 (100%)</td>
<td>5</td>
</tr>
<tr>
<td><strong>(b) Specific anaesthesia recommendations for congenital myopathies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative recommendations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Evaluation of the need for fibre-optic tracheal intubation in the presence of craniofacial abnormalities. In some forms with spinal rigidity and markedly reduced neck movement (in particular those due to variants in SELENON and NEB), intubation may be difficult.</td>
<td>3</td>
<td>9</td>
<td>17/17 (100%)</td>
<td>3</td>
</tr>
<tr>
<td>• In XLMTM, liver function tests and coagulation studies should be performed preoperatively because of potentially associated hepatic involvement [18].</td>
<td>3</td>
<td>9</td>
<td>14/14 (100%)</td>
<td>6</td>
</tr>
<tr>
<td>• Cardiac involvement is common in TTN-related myopathies and the much rarer forms due to variants in the MYH7 gene.</td>
<td>3</td>
<td>9</td>
<td>16/16 (100%)</td>
<td>4</td>
</tr>
<tr>
<td>• More specific considerations depend on the underlying pathology. Special attention to relevant respiratory involvement should be given in patients with variants in MTM, NEB, ACTA1, TTN, and RYR1 (in particular recessive variants) [20, 87]. In contrast to the muscular dystrophies, respiratory impairment may be out of proportion to the degree of limb girdle weakness (for example in NEB- and SELENON-associated forms) and must be anticipated with a high degree of suspicion [87, 88].</td>
<td>3</td>
<td>9</td>
<td>16/16 (100%)</td>
<td>4</td>
</tr>
</tbody>
</table>

(Continues)
### TABLE 5 (Continued)

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>SIGN</th>
<th>Median score, modified Delphi process</th>
<th>Respondents who scored ≥7, n</th>
<th>Abstained from voting, n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intraoperative recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• An increased bleeding tendency due to a coagulopathy has been described in patients with myotubular myopathy [18].</td>
<td>3</td>
<td>9</td>
<td>15/16 (93.8%)</td>
<td>4</td>
</tr>
<tr>
<td>• MH is mainly associated with RYR1 variants [48] that are found in dominantly or recessively inherited RYR1-related myopathies [45] and the King-Denborough syndrome [49]. Less frequently, MH has also has been described in association with variants in CACNA1S [47] or STAC3 [46]. In the case of (presumed) MH susceptibility, use of volatile anaesthetics and/or succinylcholine is strictly contraindicated [70].</td>
<td>2+</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• Nutrition needs to be monitored, as reduced muscle mass can cause postoperative hypoglycaemia up to several days after surgery [24, 26].</td>
<td>3</td>
<td>9</td>
<td>17/17 (100%)</td>
<td>3</td>
</tr>
</tbody>
</table>

Note: For each recommendation, the level of evidence according to the SIGN criteria and the level of agreement are given by the median voting results and the percentage of respondents with a voting result ≥7.

Abbreviations: AIR, anaesthesia-induced rhabdomyolysis; BMD, Becker muscular dystrophy; DMD, Duchenne muscular dystrophy; MH, malignant hyperthermia; SIGN, Scottish Intercollegiate Guidelines Network; TIVA, total intravenous anaesthesia; XLMTM, X-linked myotubular myopathy.

### Congenital myopathies

Congenital myopathies are a heterogeneous group of early onset inherited disorders. The different subtypes are traditionally based on the predominant histopathological finding: nemaline rods, cores, central nuclei, or fibre type disproportion. There is, however, overlap between these findings, and there is an emerging trend to define the conditions according to which gene is involved. There are >20 genes associated with congenital myopathies. The overall prevalence is estimated at 2–4/100,000 [86-88], with RYR1-related myopathies the most common, followed by those due to variants in NEB and ACTA1. TTN-related myopathies are increasingly diagnosed and represent an important subgroup. The genes causing congenital myopathies predominantly encode proteins implicated in skeletal muscle Ca\(^{2+}\) homeostasis, excitation-contraction coupling, myofilament assembly and interaction, and other mechanisms [88]. Specific anaesthesia considerations for patients with congenital myopathies are summarized in Table 5b.

### Mitochondrial and metabolic myopathies

#### Mitochondrial myopathies

Mitochondrial myopathies are caused by variants in either nuclear or mitochondrial DNA leading to impairment of oxidative phosphorylation or fatty acid metabolism in mitochondria. The accumulation of Acyl-CoA might result in a secondary carnitine deficiency and impair the citrate cycle, gluconeogenesis, the urea cycle, and fatty-acid oxidation, resulting in a deficit in energy production in the form of adenosine triphosphate, particularly in skeletal muscle [22, 89].

In addition, patients with a mitochondrial myopathy can also present with multisystemic symptoms. Anaesthetic preparation should therefore always be case-specific and include a multisystemic assessment. Circumstances causing metabolic disturbance should be avoided in all mitochondrial myopathies whenever possible [22, 25, 89, 90]. Specific anaesthesia considerations for patients with mitochondrial myopathies are summarized in Table 6a.

#### Metabolic myopathies

Metabolic myopathies present with either permanent (fixed) muscle symptoms or episodic abnormalities, such as exercise intolerance, activity-induced myalgia, muscle contractures, and muscle damage that can progress to rhabdomyolysis. Metabolic myopathies can be classified further as muscle glycogen storage diseases (GSDs; or muscle glycogenosis) and lipid metabolism disorders [22, 91, 92].

Muscle GSDs are a group of inherited disorders that cause glycogen to be improperly stored or utilized in the body. Symptoms and co-morbidities are highly diverse; some GSDs only affect skeletal muscle, whereas others feature involvement of other organs (including the heart and liver). This needs special focus, as patients can be severely affected multisystemically [22, 91, 92]. For instance, patients with GSD type II may present as classic Pompe disease with cardiomegaly, juvenile oligosymptomatic cases, or late onset cases with weakness and often severe respiratory involvement. Specific anaesthesia considerations for patients with GSDs are summarized in Table 6b.

Muscle lipid metabolism disorders can also manifest in organs other than skeletal muscle. Abnormalities in enzyme-processing fats can result in accumulation of fatty acid and its derivatives, including triglycerides, and sterol-containing metabolites such as cholesterol. This can be harmful to the heart and liver and may result in cardiomyopathy, arrhythmias, hepatomegaly, hypoglycaemia, and hyperammonaemia [92]. Specific anaesthesia considerations for patients with muscle lipid metabolism disorders are summarized in Table 6c.
<table>
<thead>
<tr>
<th>Recommendations</th>
<th>SIGN</th>
<th>Median score, modified Delphi process</th>
<th>Respondents who scored ≥7, n</th>
<th>Abstained from voting, n</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>(a) Specific anaesthesia recommendations for mitochondrial myopathies</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Fasting for &gt;4h should trigger a glucose drip, to be continued until oral intake is resumed [25].</td>
<td>4</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• Measurement of blood lactate levels, glucose, and serum electrolytes at baseline and during the procedure is important to monitor perioperative metabolic homeostasis.</td>
<td>4</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td><strong>Intraoperative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Mitochondrial disorders are considered to increase the risk of propofol infusion syndrome [54–56], although there are case series reporting no complications [93, 94]. The cases of propofol infusion syndrome in patients with mitochondrial disorders occurred after 3–5 days of propofol infusion [54–56]. However, propofol infusion syndrome has also been reported after &lt;1 h of infusion in healthy children and after 2h in healthy adults [53].</td>
<td>3</td>
<td>8.5</td>
<td>17/18 (94.4%)</td>
<td>2</td>
</tr>
<tr>
<td>• Propofol as an induction agent is safe [95] but should not be used for maintenance of anaesthesia. However, precaution is needed in case of preoperative metabolic deterioration [90].</td>
<td>3</td>
<td>9</td>
<td>16/16 (100%)</td>
<td>4</td>
</tr>
<tr>
<td>• Although patients may be hypersensitive, volatile anaesthetics are considered safe [1, 2, 95].</td>
<td>4</td>
<td>9</td>
<td>15/15 (100%)</td>
<td>5</td>
</tr>
<tr>
<td>• Etomidate, barbiturates, and ketamine are considered safe as induction agents [95].</td>
<td>4</td>
<td>9</td>
<td>15/15 (100%)</td>
<td>5</td>
</tr>
<tr>
<td>• Intravenous fluids administered during periods of fasting (especially in paediatric patients) should contain at least 5% glucose (except if the patient is on a ketogenic diet to control seizures). Infusion solutions should be lactate-free; electrolyte solutions containing acetate rather than lactate are preferred [96].</td>
<td>4</td>
<td>9</td>
<td>17/18 (94.4%)</td>
<td>2</td>
</tr>
<tr>
<td>• Avoid hypo- and hyperthermia.</td>
<td>4</td>
<td>9</td>
<td>18/18 (100%)</td>
<td>2</td>
</tr>
<tr>
<td><strong>Postoperative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• In the case of postoperative ICU admission and/or mechanical ventilation, the use of propofol should be limited, as there is an increased risk for propofol infusion syndrome [54–56].</td>
<td>3</td>
<td>9</td>
<td>18/18 (100%)</td>
<td>2</td>
</tr>
<tr>
<td>• Abnormal response to both hypoxaemia and hypercapnia has been observed in Leigh syndrome [97].</td>
<td>3</td>
<td>9</td>
<td>13/13 (100%)</td>
<td>7</td>
</tr>
<tr>
<td><em>(b) Specific anaesthesia recommendations for muscle glycogen storage diseases</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Avoid circumstances that may increase metabolic burden (e.g., hypo-/hyperthermia, hypoglycaemia, hypovolaemia).</td>
<td>4</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
<tr>
<td>• Fasting for &gt;4h should trigger a glucose drip, to be continued until oral intake is resumed.</td>
<td>4</td>
<td>9</td>
<td>19/19 (100%)</td>
<td>1</td>
</tr>
</tbody>
</table>

*(Continues)*
LEVEL 3: RISK PREDICTION MATRIX AND SAFETY OF NONANAESTHETIC DRUGS USED IN THE PERIOPERATIVE PERIOD

**Risk prediction matrix**

Table 7 illustrates a preoperative assessment matrix designed as a practical tool based on Schieren et al. [2], which can be used to make an inventory of the multisystem features in patients with NMDs. A grey box in the risk prediction matrix indicates that at least a subset of this group of NMDs is associated with this specific condition/complication or disease manifestation. A white box indicates that this NMD is not specifically associated with this specific condition/complication or disease manifestation.

After obtaining the relevant information, the perioperative risk can be obtained using the modified NARCO-SS tool [11]. In this risk assessment tool, a score of 0, 1, or 2 is given for each organ system and/or specific scenario in the NARCO-SS acronym. A score of 0 indicates no signs or symptoms, a score of 1 indicates mild to moderate symptoms, and a score of 2 indicates moderate to severe symptoms in the specific organ system. For the surgical severity (or “SS” in the acronym), a score of 0 is given for noninvasive or superficial elective procedures. A score of 1 is allocated for minimally invasive, elective procedures of up to 60-min duration with anticipated moderate
<table>
<thead>
<tr>
<th>Neurological signs and muscular impairment</th>
<th>Neuromuscular junction disorders</th>
<th>Muscle channelopathies</th>
<th>Myotonic dystrophies</th>
<th>Muscular dystrophies</th>
<th>Congenital muscular dystrophies</th>
<th>Congenital myopathies</th>
<th>Mitochondrial myopathies</th>
<th>Metabolic myopathies</th>
<th>Lipid metabolism disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ataxia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebral thrombosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognitive impairment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epilepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Encephalopathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myoclonus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strokelike episodes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weakness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Airway</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspiration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difficult intubation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysphagia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macroglossia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory insufficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrhythmias</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk of sudden death</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased bleeding tendency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise intolerance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactic acidosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhabdomyolysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal deformity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant hyperthermia susceptibility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myotonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: A grey box in the risk prediction matrix indicates that at least a subset of this group of neuromuscular disorders is associated with this specific condition/complication or disease manifestation. A white box indicates that this neuromuscular disorder is not specifically associated with this specific condition/complication or disease manifestation.
blood loss. A score of 2 is given for major surgery/interventions or any type of surgery in an emergency setting.

- **N**: Neurological signs & muscular impairment? [0–1–2]
- **A**: Difficult Airway? [0–1–2]
- **R**: Symptoms of Respiratory disease? [0–1–2]
- **C**: Symptoms of Cardiac disease? [0–1–2]
- **O**: Other comorbidity or metabolic concerns? [0–1–2]
- **SS**: Surgical Severity? [0–1–2]

**Result risk assessment based on modified NARCO-SS**

1. Low risk: total score 0–4 with no individual score > 1;
2. Moderate risk: total score 5–6 with no individual score > 1;
3. High risk: total score 7–9 or any individual score = 2;
4. Seriously reconsider the indication for surgery and anaesthesia when total score > 9.

**Unsafe nonanaesthetic drugs**

Anaesthetists are often asked by surgeons or other physicians to administer other drugs (e.g., antibiotics or antiepileptics). However, several of these drugs are possibly harmful for patients with NMDs. The following drugs should only be used with caution:

- Neuromuscular junction disorders
  - Oxazolidinone antibiotics (myasthenic crisis) [59, 102]
  - Aminoglycoside antibiotics (myasthenic crisis) [59, 102]
  - Beta-blocking agents (myasthenic crisis) [102]
  - Botulinum toxin (myasthenic crisis) [102]
  - Fluoroquinolone antibiotics (myasthenic crisis) [59, 102]
  - Intravenous magnesium (myasthenic crisis) [58, 102]
  - Macrolide antibiotics (myasthenic crisis) [59, 102]

- Muscle channelopathies
  - Potassium-releasing agents (hyperkalaemic periodic paralysis) [23, 63]
  - Beta-Agonist (hypokalaemic periodic paralysis) [63]
  - Insulin (hypokalaemic periodic paralysis) [63]

- Mitochondrial myopathies
  - Aminoglycoside antibiotics (ototoxicity) [95, 103]
  - Linezolid antibiotics (lactic acidosis) [95]
  - Metformin (lactic acidosis) [95, 103]
  - Valproic acid (liver failure) [95, 103]

**Open questions**

Because of the low prevalence of most NMDs, there is a lack of prospective clinical studies with a high level of evidence on the anaesthetic management of patients with NMDs, resulting in several urgent open questions [8]. Observational multicentre studies can be of great value to study the prevalence of perioperative complications in patients with NMDs and the association with certain anaesthetic agents. One of the open questions is the future role of remimazolam, a recently introduced short-acting benzodiazepine. In patients with NMDs, neither propofol or volatile anaesthetics are ideal, and short-acting benzodiazepines might be useful in this respect.

Another open question is how to manage a patient suspected of a yet undefined myopathy presenting for a procedure requiring anaesthesia (e.g., surgery, muscle biopsy, magnetic resonance imaging). If it is a diagnostic procedure, it is worth establishing whether lower risk diagnostic options, especially DNA testing, have been exhausted.

Some recommend that volatile anaesthetics be avoided. However, there is no high-level evidence on this topic, and this remains a matter of debate. Anaesthesiologists should exercise their own professional expertise and judgement to assess the disease-inherent and circumstantial risks to determine the most appropriate anaesthetic technique.

The following considerations may be helpful:

- Infants with congenital myopathies, the group at risk for MH [45, 46, 49, 50], and X-linked muscular dystrophies due to variants in the dystrophin gene, the group at risk for AIR [33, 34], usually have delayed motor milestones, but cognitive development is usually normal [19, 20, 49, 88].
- Infants with hypotonia due to a metabolic disease, the group at risk for propofol infusion syndrome [54–56], usually present with global developmental delay or other neurological signs, for example, epilepsy and spasticity [22, 91, 92].
- Although nonspecific, an increased baseline CK level possibly points to a congenital myopathy or dystrophy. Therefore, these patients might be prone to AIR or MH susceptibility, and TIVA might be the preferred option.
- Laboratory evidence of metabolic derangements (e.g., elevated basal lactates) favour a metabolic myopathy, in particular mitochondrial myopathy [22, 92]. Volatile anaesthesia might be the preferred option in such cases, as there is an increased risk of propofol infusion syndrome [54, 55].
- Although the balance of risks may be judged to favour a TIVA technique for a particular child, an intravenous induction in an infant can be very challenging or impossible even when using nitrous oxide for sedation and topical local anaesthesia. The use of a short inhalation induction is an option in this situation, subsequently changing to TIVA once the intravenous line has been secured.

Nitrous oxide, barbiturates, benzodiazepines, ketamine, opioids, rocuronium, vecuronium, and local anaesthetics are not linked to MH, AIR, propofol infusion syndrome, or other adverse events specifically linked to certain NMDs [104]. However, one must realize that there are no risk-free anaesthetic agents, as each agent has its own specific risks, especially in patients with several and severe comorbidities such as neuromuscular patients [105].
CONCLUSIONS

This consensus statement summarizes the most important recommendations concerning anaesthesia in patients with NMDs. Because there have been no RCTs and only few large retrospective studies on this topic, most evidence is based on small case series and expert opinion, highlighting the need for future research. Prospective, observational studies using common databases would be of great value and may provide answers to several unresolved questions. However, carefully curated expert opinion-based recommendations can still be of value for health care professionals in the field of anaesthesia, NMDs, and genetics. Given the low level of evidence, we expect an update of this consensus statement will be necessary in 10 years or earlier, in the case that new highly relevant evidence outdates the content of this consensus statement.

AUTHOR CONTRIBUTIONS

Luuk van den Bersselaar: Conceptualization (lead); methodology (lead); writing – original draft (lead). Luc Heytens: Conceptualization (lead); methodology (lead); writing – original draft (lead). Helga Cristina de Almeida Silva: Data curation (equal); writing – review and editing (equal). Jens Reimann: Data curation (equal); writing – original draft (equal); writing – review and editing (equal). Giorgio Tasca: Data curation (equal); writing – original draft (equal); writing – review and editing (equal). Nicoline Loekken: Data curation (equal); writing – review and editing (equal). Anna Hellblom: Data curation (equal); writing – review and editing (equal). Philip M. Hopkins: Data curation (equal); writing – review and editing (equal). Oscar Díaz-Cambronero: Data curation (equal); writing – original draft (equal); writing – review and editing (equal). Juan J Vilchez: Data curation (equal); writing – review and editing (equal). Börge Bastian: Data curation (equal); writing – review and editing (equal). Robyn Gillies: Data curation (equal); writing – review and editing (equal). Juan J Vilchez: Data curation (equal); writing – review and editing (equal). Francis Veyckemans: Data curation (equal); writing – review and editing (equal). Andrea Klein: Data curation (equal); writing – review and editing (equal). Ron Litman: Data curation (equal). H. Jungbluth: Conceptualization (equal); data curation (equal); methodology (equal); writing – review and editing (equal). Sheila Riazi: Conceptualization (equal); data curation (equal); methodology (equal); writing – review and editing (equal). Nicol Voermans: Conceptualization (equal); data curation (equal); methodology (equal); supervision (equal); writing – review and editing (equal). Marc Snoeck: Conceptualization (equal); data curation (equal); methodology (equal); supervision (equal); writing – review and editing (equal).

ACKNOWLEDGMENTS

We are thankful to the ENMC, which financially supported the 259th ENMC workshop. Several authors are members of the Radboud-NMD, NL-NMD, EURO-NMD, and TREAT-NMD consortium. We would like to dedicate this consensus statement to the late Professor Ron Litman, who participated in and contributed to the first workshop session.

CONFLICT OF INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The ENMC did not influence the content of this consensus statement.

DATA AVAILABILITY STATEMENT

The anonymized dataset generated during this study is available from the corresponding author on reasonable request from qualified investigators.

ORCID

Luuk R. van den Bersselaar https://orcid.org/0000-0001-7735-3267
Jens Reimann https://orcid.org/0000-0003-3349-6877
Giorgio Tasca https://orcid.org/0000-0003-0849-9144
Juan Jesus Vilchez https://orcid.org/0000-0002-0532-2872
Heinz Jungbluth https://orcid.org/0000-0002-7159-3427

REFERENCES

38. Muenster T, Schmidt J, Wick S, Forst J, Schmitt HJ. Rocuronium 0.3 mg x kg-1 (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne’s muscular dystrophy. Paediatr Anaesth. 2006;16:840-845.
99. Hopkins PM, Ellis FR, Halsall PJ. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant...

100. Martin JM, Gillingham MB, Harding CO. Use of propofol for short duration procedures in children with long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiencies. *Mol Genet Metab.* 2014;112:139-142.


How to cite this article: van den Bersselaar LR, Heytens L, Silva HCA, et al. European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders. *Eur J Neurol.* 2022;00:1-22. doi: [10.1111/ene.15526](https://doi.org/10.1111/ene.15526)
MANAGE-PD
Tool for Making Informed Decisions to Aid Timely Management of Parkinson’s Disease

MANAGE-PD allows you to:

- Identify PD patients inadequately controlled on oral medications
- Determine which patients with PD may be adequately controlled on their current treatment regimen or may require changes to their treatment regimen

Scan the QR code to access to the web

Click here to access to the web

MANAGE-PD is an AbbVie Inc. registered Medical Device. It is a collaborative research and development effort between AbbVie Medical Affairs and Health Economics and Outcomes, the Parkinson’s Foundation and an International panel of Movement Disorder Specialists.

©2023 AbbVie Inc. All rights reserved. The Parkinson’s Foundation logo is the sole property of the Parkinson’s Foundation used with written permission. Any use of the Parkinson’s Foundation name or logo without Foundation permission is prohibited. All content in https://www.managelpd.ca/ is intended only for informational use by healthcare professionals and is not offered as or intended to be medical advice for any particular patient. This information is not intended for patients. Only a healthcare professional exercising independent clinical judgement can make decisions regarding appropriate patient care and treatment options considering the unique characteristics of each patient.

PD: Parkinson’s Disease

Veeva Code: ABBV-AA-00335-FM Approved: January 2022